Valuation: Avadel Pharmaceuticals plc

Market Cap 2.12B 1.84B 1.73B 1.57B 2.96B 203B 3.01B 20.32B 7.93B 101B 7.97B 7.8B 339B P/E 2024
-20.5x
P/E 2025 33.7x
Enterprise Value 2B 1.73B 1.62B 1.48B 2.78B 190B 2.83B 19.09B 7.45B 95.32B 7.49B 7.33B 318B EV / Sales 2024
5.78x
EV / Sales 2025 7.12x
Free-Float
99.5%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Avadel Pharmaceuticals plc

1 day+0.05%
Current year+0.42%
Current year 21.4
Extreme 21.395
21.76
1 year 13.38
Extreme 13.38
23.57
3 years 6.38
Extreme 6.38
23.57
5 years 6.38
Extreme 6.38
23.57
10 years 6.38
Extreme 6.38
23.57
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2020-12-06
Chief Tech/Sci/R&D Officer - 2019-12-01
Investor Relations Contact - -
Date Insider Type Main position Quantity % Market Cap.
2/13/26
Weiss Asset Management LP
SellCompany 11,112,052 11.3600%
2/12/26 Issuer sale

Director

468,962 0.4794%
2/12/26 Issuer sale

Chairman

407,984 0.4171%
Change 5-day change 1-year change 3-year change Capi.($)
+0.05%-.--%+57.15% - 2.12B
-0.92%+1.43%+83.05%+128.86% 1,088B
+0.47%+1.98%+50.26%+50.75% 629B
+0.83%+2.85%+24.49%+64.82% 440B
-0.88%-0.66%+45.09%+36.64% 359B
-0.37%-1.15%+26.89%+36.31% 291B
+0.05%-1.20%+2.31%+6.15% 245B
+0.40%+3.21%+44.42%+59.17% 225B
-0.42%+1.58%-8.48%-51.94% 204B
+1.67%+5.56%+14.98%+72.68% 168B
Average +0.09%+1.49%+34.02%+44.82% 365.13B
Weighted average by Cap. -0.13%+1.47%+46.06%+65.97%

Financials

2024 2025
Net sales 169M 147M 137M 125M 236M 16.14B 240M 1.62B 632M 8.08B 635M 621M 26.95B 279M 242M 227M 207M 389M 26.64B 395M 2.67B 1.04B 13.34B 1.05B 1.03B 44.49B
Net income -48.83M -42.33M -39.68M -36.18M -68.08M -4.66B -69.17M -467M -182M -2.33B -183M -179M -7.78B 64.67M 56.06M 52.55M 47.91M 90.16M 6.17B 91.6M 619M 242M 3.09B 243M 238M 10.31B
Net Debt -34.93M -30.28M -28.39M -25.88M -48.7M -3.33B -49.48M -334M -130M -1.67B -131M -128M -5.57B -129M -112M -105M -95.5M -180M -12.3B -183M -1.23B -481M -6.16B -484M -473M -20.54B
Logo Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Employees
188
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. AVDL Stock